Key insights
- Lucid Capital Markets initiated Sensei Biotherapeutics (SNSE) with a Buy rating and a $50 price target, implying significant upside. The firm highlights the potential of PIKTOR, an oral combination therapy for endometrial and breast cancer, with key data expected by year-end 2026. While the company has sufficient cash runway, it is burning through it quickly. The analyst's positive outlook could provide a short-term boost to the stock, but the long-term impact depends on clinical trial results.
Investing.com - Lucid Capital Markets initiated coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and a price target of $50.00. The stock currently trades at $16.65, implying potential upside of roughly 200%, though the company carries a modest market capitalization of just $22.3 million.
The firm said Sensei Biotherapeutics is a clinical-stage biotechnology company developing PIKTOR, an investigational oral combination therapy consisting of two small molecules, serabelisib and sapanisertib, which is being evaluated in second-line advanced endometrial cancer and HR+/HER2- breast cancer. PIKTOR was obtained through the recent reverse merger of Faeth Therapeutics.
Lucid Capital Markets said PIKTOR is differentiated within its class by its oral route of administration and PI3Kα isoform selectivity. The firm said positive PIK-201 Phase 2 endometrial cancer topline data, expected by year-end 2026, represents the next major inflection point for shares.
The firm’s $50 price target is driven by PIKTOR in endometrial cancer at approximately $28 per share and PIKTOR in HR+/HER2- breast cancer at approximately $22 per share. Lucid Capital Markets forecasts PIKTOR could generate approximately $6.7 billion in peak non-risk adjusted worldwide revenues.
The company held cash and equivalents of approximately $203 million at first quarter 2026, which Lucid Capital Markets said should provide runway into 2028. According to InvestingPro, while the company holds more cash than debt on its balance sheet, it is quickly burning through cash. The platform’s Fair Value analysis suggests the stock is currently undervalued. Investors can access 11 additional InvestingPro Tips, along with comprehensive financial health scores and metrics to better evaluate SNSE’s investment potential.
In other recent news, Sensei Biotherapeutics has begun a Phase 1b/2 trial for its investigational therapy, PIKTOR, in patients with HR+/HER2- advanced breast cancer. This development follows the company’s acquisition of Faeth Therapeutics, which positioned PIKTOR as its lead program. PIKTOR is a combination therapy of serabelisib and sapanisertib, designed to target the PI3K/AKT/mTOR pathway. Leerink Partners initiated coverage on Sensei Biotherapeutics with an Outperform rating and set a price target of $50. These recent developments highlight the company’s ongoing efforts in cancer treatment research and its potential growth in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.